Who Exports Citalopram from India — 257 Suppliers Behind a $254.5M Market
India's citalopram export market is supplied by 257 active exporters who collectively shipped $254.5M across 7,372 shipments. MEDISPRAY LABORATORIES PRIVATE LIMITED leads with a 30.5% market share, followed by AUROBINDO PHARMA LTD and SUN PHARMACEUTICAL INDUSTRIES LIMITED. The top 5 suppliers together control 65.8% of total export value, reflecting a concentrated market structure.
Top Citalopram Exporters from India — Ranked by Export Value
MEDISPRAY LABORATORIES PRIVATE LIMITED is the leading citalopram exporter from India, holding a 30.5% share of the $254.5M market across 7,372 shipments from 257 exporters. The top 5 suppliers — MEDISPRAY LABORATORIES PRIVATE LIMITED, AUROBINDO PHARMA LTD, SUN PHARMACEUTICAL INDUSTRIES LIMITED, TORRENT PHARMACEUTICALS LTD, MYLAN LABORATORIES LIMITED — collectively control 65.8% of total export value, indicating a moderately concentrated market. Individual shares are: MEDISPRAY LABORATORIES PRIVATE LIMITED (30.5%), AUROBINDO PHARMA LTD (11.0%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (9.0%), TORRENT PHARMACEUTICALS LTD (8.5%), MYLAN LABORATORIES LIMITED (6.8%).
Top Citalopram Exporters from India
Ranked by export value · 257 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | MEDISPRAY LABORATORIES PRIVATE LIMITED S-CITAP 10 TABLETSS - CITAP 10 TABLETS - CITAP 20 TABLET | $77.6M | 1 | 30.5% |
| 2 | AUROBINDO PHARMA LTD CITALOPRAM TABLETS USP 40 MG 100BT PACKS56314ESCITALOPRAM TABLETS USP 20MGESCITALOPRAM TABLETS USP 10 MG | $28.0M | 25 | 11.0% |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED S-CITAP 10 TABLETSS - CITAP 10 TABLETS - CITAP 20 TABLET | $23.0M | 11 | 9.0% |
| 4 | TORRENT PHARMACEUTICALS LTD CITALOPRAM TABLETS USP 40 MG 100BT PACKS56314CITALOPRAM TAB 20MG PACK:BOX30S BATCH:DFESCITALOPRAM TABLETS USP 20MG | $21.7M | 15 | 8.5% |
| 5 | MYLAN LABORATORIES LIMITED CITALOPRAM TABLETS USP 40 MG 100BT PACKS56314ESCITALOPRAM TABLETS USP 20MGESCITALOPRAM TABLETS USP 10 MG | $17.3M | 4 | 6.8% |
| 6 | AUROBINDO PHARMA LIMITED CITALOPRAM TABLETS USP 40 MG 100BT PACKS56314ESCITALOPRAM TABLETS USP 20MGESCITALOPRAM TABLETS USP 10 MG | $13.5M | 14 | 5.3% |
| 7 | SANDOZ PRIVATE LIMITED CITALOPRAM TAB 20MG PACK:BOX30S BATCH:DFCITALOPRAM TAB 20MG PACK:BOX30S BATCH:ESCITALOPRAM OXA FCT 10MG IN91 SH EU 04 | $12.9M | 9 | 5.1% |
| 8 | CIPLA LIMITED S-CITAP 10 TABLETSS - CITAP 10 TABLETCITALOPRAM TABLETS USP 40 MG 100BT PACKS56314 | $8.2M | 7 | 3.2% |
| 9 | TORRENT PHARMACEUTICALS LIMITED CITALOPRAM TABLETS USP 40 MG 100BT PACKS56314CITALOPRAM TAB 20MG PACK:BOX30S BATCH:DFESCITALOPRAM TABLETS USP 20MG | $7.0M | 13 | 2.8% |
| 10 | IPCA LABORATORIES LIMITED ESCITALOPRAM SANDOZ 20 MG THARMLESS MEDICINES:CITALOPRAM 20MG TABLETSCITALOPRAM 20MG TABLETS | $6.0M | 9 | 2.4% |
| 11 | GRAVITI PHARMACEUTICALS PRIVATE LIMITED CITALOPRAM TABLETS USP 40 MG 100BT PACKS56314ESCITALOPRAM TABLETS USP 20MGESCITALOPRAM TABLETS USP 10 MG | $5.4M | 1 | 2.1% |
| 12 | INTAS PHARMACEUTICALS LIMITED ESCITALOPRAM OXA FCT 10MG IN91 SH EU 04HARMLESS MEDICINES:CITALOPRAM 20MG TABLETSCITALOPRAM 20MG TABLETS | $4.1M | 11 | 1.6% |
| 13 | GALPHA LABORATORIES LIMITED. CITALOPRAM TABLETS 20MGCITALOPRAM 20MG TABLETS 2X14S 193895CITALOPRAM 20MG TABLETS 2X14S191105 PAC | $3.8M | 1 | 1.5% |
| 14 | MICRO LABS LIMITED CITALOPRAM SUN TABLETS 20MG PACK : BOX 2CITALOPRAM TABLETS 40MG PACK : BOX 2X14SCITALOPRAM TAB 20MG 2X14B UK PACK : BOX | $3.2M | 10 | 1.3% |
| 15 | APOTEX RESEARCH PRIVATE LIMITED ESCITALOPRAM TABLETS USP 10MG (AURO-ESCIAPO-ESCITALOPRAM FCT 10MG 100 BTL 51667/APO-ESCITALOPRAM FCT 20MG 100 BTL 51668/ | $2.4M | 1 | 0.9% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Citalopram exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Aurobindo Pharma Limited | Approved | Yes | Yes | Multiple | FDA warning letter issued on June 20, 2019, for Pydibhimavaram facility. |
| Sun Pharmaceutical Industries Limited | Approved | Yes | Yes | Multiple | No FDA warning letters found. |
| Torrent Pharmaceuticals Limited | Approved | Yes | Yes | Multiple | FDA warning letter issued in May 2011; specific facility not detailed. |
| Mylan Laboratories Limited | Approved | Yes | Yes | Multiple | No FDA warning letters found. |
| Cipla Limited | Approved | Yes | Yes | Multiple | No FDA warning letters found. |
| Intas Pharmaceuticals Limited | Approved | Yes | Yes | Multiple | No FDA warning letters found. |
| Micro Labs Limited | Approved | Yes | Yes | Multiple | No FDA warning letters found. |
| Apotex Research Private Limited | Approved | Yes | Yes | Multiple | No FDA warning letters found. |
TransData Nexus reviewed the regulatory standing of 8 leading Citalopram exporters from India. 8 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Citalopram sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as India's "Bulk Drug Capital," is a pivotal hub for Active Pharmaceutical Ingredients (APIs) and bulk drug manufacturing. The city hosts over 800 pharmaceutical companies, including major players like Dr. Reddy's Laboratories and Aurobindo Pharma. The presence of Genome Valley, India's first biotech cluster, underscores Hyderabad's emphasis on research and development in the pharmaceutical sector.
The city's robust infrastructure, skilled workforce, and supportive government policies have fostered a conducive environment for pharmaceutical manufacturing. Hyderabad's strategic location and well-established supply chain networks further enhance its appeal for API production and export activities.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations manufacturing. Gujarat contributes nearly 28% of India's pharmaceutical production, with over 3,300 pharmaceutical units operating in the state. Companies such as Zydus Cadila, Intas Pharmaceuticals, and Torrent Pharmaceuticals have established significant operations in this region.
The region's well-developed infrastructure, including proximity to major ports, facilitates efficient export operations. Additionally, the presence of a skilled workforce and a favorable regulatory environment make Ahmedabad and Vadodara attractive destinations for pharmaceutical manufacturing and export.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt in Maharashtra serves as a critical export gateway for India's pharmaceutical industry. With approximately 929 pharmaceutical units, Maharashtra is a significant contributor to the country's pharmaceutical output. Mumbai's status as a financial hub, coupled with its well-established logistics and port facilities, positions it as a strategic location for pharmaceutical exports.
The region's proximity to international markets and its comprehensive infrastructure support the efficient distribution of pharmaceutical products, including Citalopram, to global destinations.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi and Nalagarh in Himachal Pradesh have emerged as prominent pharmaceutical manufacturing zones, primarily due to favorable tax incentives and government policies. Baddi is home to over 1,000 pharmaceutical companies, including major players like Cipla, Dr. Reddy's Laboratories, and Torrent Pharmaceuticals.
The region's strategic location, coupled with a skilled workforce and supportive infrastructure, has made it a preferred destination for pharmaceutical manufacturing. However, companies should consider potential logistical challenges associated with the hilly terrain when planning export operations.
5Sourcing Recommendations
- Diversify Supplier Base: While the top five exporters account for a significant portion of Citalopram exports, engaging with a broader range of suppliers can mitigate risks associated with over-reliance on a few sources.
- Evaluate Regional Advantages: Assess the specific strengths of each pharmaceutical cluster—such as Hyderabad's API production capabilities or Ahmedabad's formulations expertise—to align sourcing strategies with regional specializations.
- Consider Logistical Factors: Factor in the logistical advantages of regions like Mumbai-Thane-Raigad for export operations, given their proximity to major ports and international markets.
- Monitor Regulatory Compliance: Ensure that selected suppliers adhere to international regulatory standards, leveraging regions with established compliance records to facilitate smoother market entry.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Citalopram exporters from India
Sun Pharmaceutical Industries Limited — Sun Pharma acquires Checkpoint Therapeutics for $355 million
In March 2025, Sun Pharma announced the acquisition of Checkpoint Therapeutics, a Waltham, Massachusetts-based company specializing in immunotherapy and targeted oncology treatments, for $355 million. IMPACT: This acquisition is expected to enhance Sun Pharma's oncology portfolio, potentially influencing its strategic focus and resource allocation, which may indirectly affect its Citalopram export activities.
Impact: This acquisition is expected to enhance Sun Pharma's oncology portfolio, potentially influencing its strategic focus and resource allocation, which may indirectly affect its Citalopram export activities.
Sun Pharmaceutical Industries Limited — Sun Pharma merges with Taro Pharmaceuticals in $347.73 million deal
In January 2024, Sun Pharma entered into a definitive merger agreement with Taro Pharmaceuticals, acquiring the remaining stake for $347.73 million. This move aimed to consolidate Sun Pharma's position in the generic pharmaceutical market. IMPACT: The merger is likely to strengthen Sun Pharma's market presence, potentially impacting its production and export strategies, including those related to Citalopram.
Impact: The merger is likely to strengthen Sun Pharma's market presence, potentially impacting its production and export strategies, including those related to Citalopram.
Sun Pharmaceutical Industries Limited — Sun Pharma partners with Pharmazz for ischemic stroke drug in India
In September 2023, Sun Pharma entered into a licensing agreement with Pharmazz Inc. to introduce an ischemic stroke drug in India, expanding its neurology portfolio. IMPACT: This collaboration may enhance Sun Pharma's neurology offerings, potentially affecting its focus and resources allocated to Citalopram exports.
Impact: This collaboration may enhance Sun Pharma's neurology offerings, potentially affecting its focus and resources allocated to Citalopram exports.
Common Questions — Citalopram Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which citalopram supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, MEDISPRAY LABORATORIES PRIVATE LIMITED leads with 77 recorded shipments worth $77.6M. AUROBINDO PHARMA LTD (1,035 shipments) and SUN PHARMACEUTICAL INDUSTRIES LIMITED (463 shipments) are also established high-volume exporters.
Q How many citalopram manufacturers are there in India?
India has 257 active citalopram exporters with a combined export market of $254.5M across 7,372 shipments to 101 countries. The top 5 suppliers hold 65.8% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for citalopram from India?
Average FOB unit price: $3.57 per unit, ranging from $0.00 to $978.18. Average shipment value: $34.5K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 257 verified Indian exporters of Citalopram ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 7,372 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 101 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
7,372 Verified Shipments
257 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists